Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lia M. Haynes is active.

Publication


Featured researches published by Lia M. Haynes.


Nature Immunology | 2000

Pattern recognition receptors TLR4 and CD14 mediate response to respiratorysyncytial virus

Evelyn A. Kurt-Jones; Lana Popova; Laura Kwinn; Lia M. Haynes; Les P. Jones; Ralph A. Tripp; Edward E. Walsh; Mason W. Freeman; Douglas T. Golenbock; Larry J. Anderson; Robert W. Finberg

The innate immune system contributes to the earliest phase of the host defense against foreign organisms and has both soluble and cellular pattern recognition receptors for microbial products. Two important members of this receptor group, CD14 and the Toll-like receptor (TLR) pattern recognition receptors, are essential for the innate immune response to components of Gram-negative and Gram-positive bacteria, mycobacteria, spirochetes and yeast. We now find that these receptors function in an antiviral response as well. The innate immune response to the fusion protein of an important respiratory pathogen of humans, respiratory syncytial virus (RSV), was mediated by TLR4 and CD14. RSV persisted longer in the lungs of infected TLR4-deficient mice compared to normal mice. Thus, a common receptor activation pathway can initiate innate immune responses to both bacterial and viral pathogens.


The New England Journal of Medicine | 2015

Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults

Seema Jain; Derek J. Williams; Sandra R. Arnold; Krow Ampofo; Anna M. Bramley; Carrie Reed; Chris Stockmann; Evan J. Anderson; Carlos G. Grijalva; Wesley H. Self; Yuwei Zhu; Anami Patel; Weston Hymas; James D. Chappell; Robert A. Kaufman; J. Herman Kan; David Dansie; Noel Lenny; David R. Hillyard; Lia M. Haynes; Min Z. Levine; Stephen Lindstrom; Jonas M. Winchell; Jacqueline M. Katz; Dean D. Erdman; Eileen Schneider; Lauri A. Hicks; Richard G. Wunderink; Kathryn M. Edwards; Andrew T. Pavia

BACKGROUND Community-acquired pneumonia is a leading infectious cause of hospitalization and death among U.S. adults. Incidence estimates of pneumonia confirmed radiographically and with the use of current laboratory diagnostic tests are needed. METHODS We conducted active population-based surveillance for community-acquired pneumonia requiring hospitalization among adults 18 years of age or older in five hospitals in Chicago and Nashville. Patients with recent hospitalization or severe immunosuppression were excluded. Blood, urine, and respiratory specimens were systematically collected for culture, serologic testing, antigen detection, and molecular diagnostic testing. Study radiologists independently reviewed chest radiographs. We calculated population-based incidence rates of community-acquired pneumonia requiring hospitalization according to age and pathogen. RESULTS From January 2010 through June 2012, we enrolled 2488 of 3634 eligible adults (68%). Among 2320 adults with radiographic evidence of pneumonia (93%), the median age of the patients was 57 years (interquartile range, 46 to 71); 498 patients (21%) required intensive care, and 52 (2%) died. Among 2259 patients who had radiographic evidence of pneumonia and specimens available for both bacterial and viral testing, a pathogen was detected in 853 (38%): one or more viruses in 530 (23%), bacteria in 247 (11%), bacterial and viral pathogens in 59 (3%), and a fungal or mycobacterial pathogen in 17 (1%). The most common pathogens were human rhinovirus (in 9% of patients), influenza virus (in 6%), and Streptococcus pneumoniae (in 5%). The annual incidence of pneumonia was 24.8 cases (95% confidence interval, 23.5 to 26.1) per 10,000 adults, with the highest rates among adults 65 to 79 years of age (63.0 cases per 10,000 adults) and those 80 years of age or older (164.3 cases per 10,000 adults). For each pathogen, the incidence increased with age. CONCLUSIONS The incidence of community-acquired pneumonia requiring hospitalization was highest among the oldest adults. Despite current diagnostic tests, no pathogen was detected in the majority of patients. Respiratory viruses were detected more frequently than bacteria. (Funded by the Influenza Division of the National Center for Immunizations and Respiratory Diseases.).


Journal of Virology | 2001

Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus.

Lia M. Haynes; Deborah Moore; Evelyn A. Kurt-Jones; Robert W. Finberg; Larry J. Anderson; Ralph A. Tripp

ABSTRACT The mammalian Toll-like receptor 4, TLR4, is an important component in the innate immune response to gram-negative bacterial infection. The role of TLR4 in antiviral immunity has been largely unexplored. In this study, the in vivo immune responses to respiratory syncytial virus (RSV) and influenza virus infection were examined in TLR4-deficient (C57BL/10ScNCr) and TLR4-expressing (C57BL/10Sn) mice. TLR4-deficient mice challenged with RSV, but not influenza virus, exhibited impaired natural killer (NK) cell and CD14+ cell pulmonary trafficking, deficient NK cell function, impaired interleukin-12 expression, and impaired virus clearance compared to mice expressing TLR4. These findings suggest that Toll signaling pathways have an important role in innate immunity to RSV.


Nature Immunology | 2001

CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein.

Ralph A. Tripp; Les P. Jones; Lia M. Haynes; HaoQiang Zheng; Philip M. Murphy; Larry J. Anderson

Chemokines are chemoattractant proteins that are divided into subfamilies based upon cysteine signature motifs termed C, CC, CXC and CX3C. Chemokines have roles in immunity and inflammation that affect cell trafficking and activation of T cells as well as cells of the innate immune system. We report here CX3C chemokine mimicry for the G glycoprotein of respiratory syncytial virus (RSV) and show binding to CX3CR1—the specific receptor for the CX3C chemokine fractalkine—and induction of leukocyte chemotaxis. We also show that CX3CR1 facilitates RSV infection of cells. Thus, G glycoprotein interaction with CX3CR1 probably plays a key role in the biology of RSV infection.


Journal of Virology | 2009

Respiratory Syncytial Virus Activates Innate Immunity through Toll-Like Receptor 2

Matthew R. Murawski; Glennice N. Bowen; Anna M. Cerny; Larry J. Anderson; Lia M. Haynes; Ralph A. Tripp; Evelyn A. Kurt-Jones; Robert W. Finberg

ABSTRACT Respiratory syncytial virus (RSV) is a common cause of infection that is associated with a range of respiratory illnesses, from common cold-like symptoms to serious lower respiratory tract illnesses such as pneumonia and bronchiolitis. RSV is the single most important cause of serious lower respiratory tract illness in children <1 year of age. Host innate and acquired immune responses activated following RSV infection have been suspected to contribute to RSV disease. Toll-like receptors (TLRs) activate innate and acquired immunity and are candidates for playing key roles in the host immune response to RSV. Leukocytes express TLRs, including TLR2, TLR6, TLR3, TLR4, and TLR7, that can interact with RSV and promote immune responses following infection. Using knockout mice, we have demonstrated that TLR2 and TLR6 signaling in leukocytes can activate innate immunity against RSV by promoting tumor necrosis factor alpha, interleukin-6, CCL2 (monocyte chemoattractant protein 1), and CCL5 (RANTES). As previously noted, TLR4 also contributes to cytokine activation (L. M. Haynes, D. D. Moore, E. A. Kurt-Jones, R. W. Finberg, L. J. Anderson, and R. A. Tripp, J. Virol. 75:10730-10737, 2001, and E. A. Kurt-Jones, L. Popova, L. Kwinn, L. M. Haynes, L. P. Jones, R. A. Tripp, E. E. Walsh, M. W. Freeman, D. T. Golenbock, L. J. Anderson, and R. W. Finberg, Nat. Immunol. 1:398-401, 2000). Furthermore, we demonstrated that signals generated following TLR2 and TLR6 activation were important for controlling viral replication in vivo. Additionally, TLR2 interactions with RSV promoted neutrophil migration and dendritic cell activation within the lung. Collectively, these studies indicate that TLR2 is involved in RSV recognition and subsequent innate immune activation.


Clinical Infectious Diseases | 2014

Hospital-associated outbreak of Middle East Respiratory Syndrome Coronavirus: A serologic, epidemiologic, and clinical description

Mohammad Mousa Al-Abdallat; Daniel C. Payne; Sultan Alqasrawi; Brian Rha; Rania A. Tohme; Glen R. Abedi; Mohannad Al Nsour; Ibrahim Iblan; Najwa Jarour; Noha H. Farag; Aktham Haddadin; Tarek Alsanouri; Azaibi Tamin; Jennifer L. Harcourt; David T. Kuhar; David L. Swerdlow; Dean D. Erdman; Mark A. Pallansch; Lia M. Haynes; Susan I. Gerber

Novel serological tests allowed for the detection of otherwise unrecognized cases of Middle East respiratory syndrome coronavirus infection among contacts in a hospital-associated respiratory illness outbreak in Jordan in April 2012, resulting in a total of 9 test-positive cases.


Emerging Infectious Diseases | 2009

Detection of Novel SARS-like and Other Coronaviruses in Bats from Kenya

Suxiang Tong; Christina Conrardy; Susan Ruone; Ivan V. Kuzmin; Xiling Guo; Ying Tao; Michael Niezgoda; Lia M. Haynes; Bernard Agwanda; Robert F. Breiman; Larry J. Anderson; Charles E. Rupprecht

Diverse coronaviruses have been identified in bats from several continents but not from Africa. We identified group 1 and 2 coronaviruses in bats in Kenya, including SARS-related coronaviruses. The sequence diversity suggests that bats are well-established reservoirs for and likely sources of coronaviruses for many species, including humans.


Journal of Virology | 2003

Enhanced Disease and Pulmonary Eosinophilia Associated with Formalin-Inactivated Respiratory Syncytial Virus Vaccination Are Linked to G Glycoprotein CX3C-CX3CR1 Interaction and Expression of Substance P

Lia M. Haynes; Les P. Jones; Albert E. Barskey; Larry J. Anderson; Ralph A. Tripp

ABSTRACT Vaccination with formalin-inactivated respiratory syncytial virus (FI-RSV) vaccine or RSV G glycoprotein results in enhanced pulmonary disease after live RSV infection. Enhanced pulmonary disease is characterized by pulmonary eosinophilia and is associated with a substantial inflammatory response. We show that the absence of the G glycoprotein or G glycoprotein CX3C motif during FI-RSV vaccination or RSV challenge of FI-RSV-vaccinated mice, or treatment with anti-substance P or anti-CX3CR1 antibodies, reduces or eliminates enhanced pulmonary disease, modifies T-cell receptor Vβ usage, and alters CC and CXC chemokine expression. These data suggest that the G glycoprotein, and in particular the G glycoprotein CX3C motif, is key in the enhanced inflammatory response to FI-RSV vaccination, possibly through the induction of substance P.


Emerging Infectious Diseases | 2004

Laboratory Diagnosis of Four Recent Sporadic Cases of Community-acquired SARS, Guangdong Province, China

Guodong Liang; Qiuxia Chen; Jianguo Xu; Yufei Liu; Wilina Lim; J. S. M. Peiris; Larry J. Anderson; Li Ruan; Hui Li; Biao Kan; Biao Di; Peter K.C. Cheng; Kh Chan; Dean D. Erdman; Shuyan Gu; Xinge Yan; Weili Liang; Duan-Hua Zhou; Lia M. Haynes; Shumin Duan; Xin Zhang; Han Zheng; Yang Gao; Suxiang Tong; Dexin Li; Ling Fang; Pengzhe Qin; Wenbo Xu

Four sporadic cases of SARS-associated coronavirus infection were identified through collaboration of four laboratories.


The Journal of Infectious Diseases | 2009

Therapeutic Monoclonal Antibody Treatment Targeting Respiratory Syncytial Virus (RSV) G Protein Mediates Viral Clearance and Reduces the Pathogenesis of RSV Infection in BALB/c Mice

Lia M. Haynes; Hayat Caidi; Gertrud U. Radu; Congrong Miao; Jennifer L. Harcourt; Ralph A. Tripp; Larry J. Anderson

Because the G protein of respiratory syncytial virus (RSV) has a CX3C chemokine motif that has been associated with the ability of RSV G protein to modulate the virus-induced host immune response, we examined whether therapeutic treatment with an anti-RSV G monoclonal antibody (mAb), 131-2G, that blocks the CX3C-associated activity of RSV G protein might decrease the pulmonary inflammation associated with infection in BALB/c mice. The results show that treatment with mAb 131-2G on day 3 after RSV infection reduces both inflammation and RSV titer in the lungs. Later administration of anti-RSV G mAb (day 5 after RSV infection) effectively reduced the viral titer but had a minimal effect on pulmonary inflammation. This study suggests that an anti-RSV G mAb might be an effective antiviral, either alone or in combination with anti-RSV F protein neutralizing antibodies, for decreasing the virus-induced host response to infection and improve treatment outcome.

Collaboration


Dive into the Lia M. Haynes's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jennifer L. Harcourt

National Center for Immunization and Respiratory Diseases

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Congrong Miao

National Center for Immunization and Respiratory Diseases

View shared research outputs
Top Co-Authors

Avatar

David L. Swerdlow

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Hayat Caidi

National Center for Immunization and Respiratory Diseases

View shared research outputs
Top Co-Authors

Avatar

Dean D. Erdman

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Azaibi Tamin

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

David T. Kuhar

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge